Dan Junius

Track

Insider profile

Currently holds positions in IDEXX Laboratories, Inc. and Crescent Biopharma, Inc.

Performance

Overall performance
2.6
Performance over holding periods
2.6
30 days 90 days 120 days
Average return 1% 8.2% 15.1%
Success rate 64% 68% 82%
Transactions
12 42% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director IDEXX Laboratories, Inc. March 11, 2014 -
Independent Director Crescent Biopharma, Inc. March 17, 2016 -
Independent Director Vitae Pharmaceuticals LLC July 27, 2016 - Oct. 25, 2016
President, Chief Executive Officer, Director ImmunoGen Inc Dec. 30, 2013 - May 16, 2016
President, Chief Executive Officer, Interim Chief Financial Officer, Director ImmunoGen Inc Sept. 13, 2013 - Dec. 30, 2013
President, Chief Executive Officer, Director ImmunoGen Inc Jan. 1, 2009 - Sept. 13, 2013
Dan Junius's trades of IDEXX Laboratories, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Sale
Price
27.65
Quantity 99,305 +42.5%
Value US$2,510,310
Transaction date
Proposed sale
Price
311.23
Quantity 85,036
Value US$1,526,318
Transaction date
Purchase
Price
234.21
Quantity 58,335 +27.5%
Value US$2,739,037
Transaction date
Sale
Price
424.91
Quantity 3,046 -50.6%
Value US$1,294,276
Transaction date
Sale
Price
539.57
Quantity 2,500 -46.4%
Value US$1,348,918
Transaction date
Sale
Price
538.57
Quantity 1,888 -39.6%
Value US$1,016,815
Transaction date
Sale
Price
539.19
Quantity 10 -0.2%
Value US$5,392
Transaction date
Sale
Price
382.61
Quantity 3,722 -56.7%
Value US$1,424,063
Transaction date
Purchase
Price
3.18
Quantity 10,000 +125.0%
Value US$31,800
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-05-14 2025-05-13
S Sale
99,305 +42.5%
27.65
US$2,510,310 		99,305 +42.5% 27.65 US$2,510,310
2025-05-13 2025-05-13
PrS Proposed sale
85,036
311.23
US$1,526,318 		85,036 311.23 US$1,526,318
2023-05-11 2023-05-10
B Purchase
58,335 +27.5%
234.21
US$2,739,037 		58,335 +27.5% 234.21 US$2,739,037
2023-02-17 2023-02-16
S Sale
2,187 -42.3%
511.68
US$1,119,044 		2,187 -42.3% 511.68 US$1,119,044
2022-12-07 2022-12-05
S Sale
3,046 -50.6%
424.91
US$1,294,276 		3,046 -50.6% 424.91 US$1,294,276
2022-11-18 2022-11-17
B Purchase
20,000 +46.2%
1.87
US$37,400 		20,000 +46.2% 1.87 US$37,400
2021-05-24 2021-05-21
S Sale
2,500 -46.4%
539.57
US$1,348,918 		2,500 -46.4% 539.57 US$1,348,918
2021-02-24 2021-02-22
S Sale
1,888 -39.6%
538.57
US$1,016,815 		1,888 -39.6% 538.57 US$1,016,815
2021-02-24 2021-02-22
S Sale
10 -0.2%
539.19
US$5,392 		10 -0.2% 539.19 US$5,392
2020-08-21 2020-08-20
S Sale
3,722 -56.7%
382.61
US$1,424,063 		3,722 -56.7% 382.61 US$1,424,063
2020-03-10 2020-03-09
B Purchase
20,000 +111.1%
3.40
US$68,000 		20,000 +111.1% 3.40 US$68,000
2019-08-15 2019-08-13
B Purchase
10,000 +125.0%
3.18
US$31,800 		10,000 +125.0% 3.18 US$31,800
2016-12-21 2016-12-20
B Purchase
5,000 +inf%
6.01
US$30,050 		5,000 +inf% 6.01 US$30,050